account_id none on file
legal_name Immunocore Holdings plc
ticker IMCR
cik 1671927
domain immunocore.com
linkedin_company_url https://www.linkedin.com/company/immunocore
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 3 executives 0 family 0
why_nownone on file
callsnone on file
filings
• the planned geographic expansion and expansion of patient reach for KIMMTRAK; • the plans for expansion and growth into new melanoma indications, beyond melanoma into other tumor types, and beyond oncology; • the safety, efficacy and clinical progress of our various ongoing clinical programs and any planned clinical programs, including those for tebentafusp, brenetafusp, IMC-P115C, IMC-R117C, IMC-M113V, IMC-S11
filing / Aug 6, 2026 / receipt
For the three months ended March 31, 2026, our internal R&D expenses increased by $3.8 million primarily due to increases in salaries and other employee-related costs following the growth of our clinical and preclinical programs and associated headcount increases.
filing / May 6, 2026 / receipt
• the planned geographic expansion and expansion of patient reach for KIMMTRAK; • the plans for expansion and growth into new melanoma indications, beyond melanoma into other tumor types, and beyond oncology; • the safety, efficacy and clinical progress of our various ongoing clinical programs and any planned clinical programs, including those for tebentafusp, brenetafusp, IMC-P115C, IMC-R117C, IMC-M113V, IMC-S11
filing / May 6, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug immunocore-holdings-plc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$